Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;9(4):1041-1053.
doi: 10.1007/s40123-020-00307-0. Epub 2020 Oct 7.

Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma

Constance O Okeke  1 , Eitan S Burstein  2 , Valerie Trubnik  3 , James E Deom  4 , Michael S Cooper  5 , Desirae A Brinkley  6 , J James Thimons  7 , Alexander J Kabiri  8 , Kerry M Gelb  9
Affiliations

Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma

Constance O Okeke et al. Ophthalmol Ther. 2020 Dec.

Abstract

Introduction: The objective of this study was to evaluate real-world effectiveness of latanoprostene bunod (LBN) ophthalmic solution 0.024% in treatment-naïve patients newly diagnosed with open-angle glaucoma (OAG) or ocular hypertension.

Methods: This multicenter retrospective chart review included patients aged ≥ 18 years, with no history of medical, laser, or surgical intraocular pressure (IOP)-lowering intervention and at least two follow-up visits (spanning ≥ 2 months) following initiation of LBN treatment. Extracted data included age, sex, race, cup-to-disk ratio, central corneal thickness, IOP, visual acuity (VA), concomitant medications, and adverse events. In patients treated bilaterally, the eye with the higher baseline IOP was the study eye.

Results: Medical charts for 65 patients (mean [SD] age, 59 [14] years; 53.8% female) encompassing 125 eyes treated with LBN were reviewed across nine clinical sites. Mean (SD) IOP at baseline was 21.7 (5.9) mmHg. Mean days to first and second follow-up visit were 43 and 141, respectively. LBN use resulted in a mean (SD) reduction from baseline of 7.1 (4.7) and 7.3 (5.1) mmHg at the first and second follow-up visits, respectively (P < 0.0001 for both). Reductions among patients with IOP > 21 mmHg (n = 30) at baseline were 10.0 (4.5) and 11.1 (4.6) mmHg at the first and second follow-up visits (P < 0.0001 for both). There were no meaningful changes in VA. Adverse events appeared infrequent, with only one report of ocular redness.

Conclusion: In this real-world, retrospective chart review, LBN 0.024% use resulted in robust IOP lowering in newly diagnosed OAG patients new to treatment, and appeared well tolerated.

Keywords: Intraocular pressure; Latanoprostene bunod; Ocular hypertension; Open-angle glaucoma; Retrospective.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Change in intraocular pressure overall and by baseline IOP. IOP intraocular pressure. P < 0.0001 for all changes from baseline
Fig. 2
Fig. 2
Percent responders at follow-up visit 1 (a) and follow-up visit 2 (b). IOP intraocular pressure
Fig. 3
Fig. 3
Concomitant IOP-lowering medications and medication switches. IOP intraocular pressure, LBN latanoprostene bunod 0.024%
See this image and copyright information in PMC

References

    1. Gupta P, Zhao D, Guallar E, Ko F, Boland MV, Friedman DS. Prevalence of glaucoma in the United States: the 2005–2008 National Health and Nutrition Examination Survey. Invest Ophthalmol Vis Sci. 2016;57(6):2905–2913. - PMC - PubMed
    1. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221–e1234. - PubMed
    1. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017;390(10108):2183–2193. - PubMed
    1. Trivli A, Koliarakis I, Terzidou C, Goulielmos GN, Siganos CS, Spandidos DA, et al. Normal-tension glaucoma: pathogenesis and genetics. Exp Ther Med. 2019;17(1):563–574. - PMC - PubMed
    1. Weinreb RN, Lueng CK, Crowston JG, Medeiros FA, Friedman DS, Wiggs JL, et al. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016;2:16067. - PubMed

LinkOut - more resources